Home / Fact sheets / Morocco / Cervical qualitative data

Country fact sheet: Morocco


Reporting year for qualitative data: 2021
Source of qualitative data: Directly from Programme

Organization of screening

An individual/team/institution responsible to coordinate the programme: Yes
Dedicated budget for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Notification
Year programme was initiated: 2010
Programme introduction was preceded by a pilot: Yes, pilot evaluated and report published
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: No
Treatment services provided free of charge: No

Information system and data collection

System that collects data: Aggregated
   • Identification of eligible population: -
   • Screening participation: Aggregated
   • Screening test results: Aggregated
   • Further assessment: Aggregated
   • Final pathology diagnosis: Aggregated
   • Cancer staging: No
   • Treatment: No
The information system exists at national or sub-national level: Individual: Unknown
Aggregated: Sub-national
The information system collects data outside the programme (opportunistic screening/private sector): No
Cancer screening data is linked with population-based cancer registry (PBCR): PBCR exists but not linked

Screening protocol

A screening protocol or guideline: Yes
Year of published/updated protocol: 2011
Target age (min-max) and screening interval [months] for each test: VIA (30-49 years / [36 months])
Triaging test used: None
Self-collection HPV recommended: -
"Screen and treat" included in the protocol: No
Treatment modality for "screen and treat": -

Invitations for screening and further assessment

Initiatives to create population awareness by the Health Ministry/Health Authority: Small media campaign
Group education
One-on-one education
Invitations to eligible population: No
Source of the eligible individuals identified: -
Method of invitation: -
Screening kit included with the invitation: -
Screen positive individuals actively contacted for further assessment: Yes
Individuals with a precancer or cancer diagnosis actively contacted: Yes

Quality Assurance (QA) of screening activities

Documented standard operating procedure/policy for QA: No
An individual/team/institution responsible for QA: No
Accreditation of lab services: No
Accreditation of pathology services: No
Documented performance indicators: Yes
Reference standards for performance indicators: Yes
Evaluation reports published in the last five years: No

Performance indicators

Reporting year for quantitative data: 2019
Source of quantitative data: Directly from programme
Age range and regional limitation if applicable: VIA (30-49 years)
Invitation coverage (%):
Participation rate (%):
Examination coverage (%): 27.3
Completeness of data related to screening test results (%): 100.0
Completeness of data related to further assessment results (%):
Further assessment (Colposcopy referral) rate (%): 3.6
Further assessment participation rate (%): 73.9
Detection rate for CIN2+ (x 1000): 0.55
Detection rate for CIN3+ (x 1000): 0.35
Detection rate for invasive cancer (x 1000): 0.0
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): 2.1
Positive Predictive Value for CIN3+ (x 1000): 1.3
Positive Predictive Value for invasive cancer (x 1000): 0.0
More quantitative data (2019/VIA)

Check also the following factsheets: Morocco, Breast, Colorectal